{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:01:40Z","timestamp":1792738900110,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rabies remains a devastating and fatal infectious disease worldwide. To date, vaccination is the most reliable and effective strategy for controlling rabies. However, despite the effectiveness of inactivated vaccines, cumbersome vaccination procedures and the high costs of post-exposure prophylaxis impose a significant economic burden, particularly in developing countries with limited access to vaccines. Therefore, there is an urgent need to develop a novel rabies vaccine that reduces costs while enhancing safety and efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We developed a novel mRNA rabies vaccine called RABV-G-LT, which incorporates two immunogens: RABV-G, a glycoprotein designed mainly to elicit neutralizing antibody responses, and RABV-LT, a T-cell immunogen derived from the large protein of the rabies virus. Additionally, we evaluated the immunogenicity of RABV-G-LT in both mice and non-human primates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The RABV-LT mRNA vaccination alone induced potent RABV-LT-specific T-cell responses and provided modest protection against rabies virus challenge in mice. Importantly, the dual-immunogen mRNA vaccine RABV-G-LT elicited vigorous and persistent neutralization antibody and T-cell responses, resulting in significantly more efficient clearance of the rabies virus in the brain and spinal cord. This conferred enhanced protection, evidenced by lesser initial weight loss and earlier recovery of body weight compared with the RABV-G mRNA or inactivated vaccine groups. Moreover, RABV-G-LT also mounted persistent strong antigen-specific T-cell and antibody immune responses in nonhuman primates.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study suggested that combining the T-cell immunogen and virus-neutralizing antibody immunogen was a practical approach to strengthening the defense against the rabies virus.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s43856-025-00851-5","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:41:02Z","timestamp":1744972862000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rabies virus large protein-derived T-cell immunogen facilitates rapid viral clearance and enhances protection against lethal challenge in mice"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-1934","authenticated-orcid":false,"given":"Shimeng","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6400-4399","authenticated-orcid":false,"given":"Xinghao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuisong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-1401","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-9273","authenticated-orcid":false,"given":"Jianqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.91","volume":"3","author":"AR Fooks","year":"2017","unstructured":"Fooks, A. R. et al. Rabies. Nat. Rev. Dis. Prim. 3, 17091 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"851_CR2","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","volume":"28","author":"N Johnson","year":"2010","unstructured":"Johnson, N., Cunningham, A. F. & Fooks, A. R. The immune response to rabies virus infection and vaccination. Vaccine 28, 3896\u20133901 (2010).","journal-title":"Vaccine"},{"key":"851_CR3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.tim.2018.07.001","volume":"26","author":"K Brunker","year":"2018","unstructured":"Brunker, K. & Mollentze, N. Rabies virus. Trends Microbiol. 26, 886\u2013887 (2018).","journal-title":"Trends Microbiol."},{"key":"851_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10875-006-9044-0","volume":"26","author":"SM Moore","year":"2006","unstructured":"Moore, S. M., Wilkerson, M. J., Davis, R. D., Wyatt, C. R. & Briggs, D. J. Detection of cellular immunity to rabies antigens in human vaccinees. J. Clin. Immunol. 26, 533\u2013545 (2006).","journal-title":"J. Clin. Immunol."},{"key":"851_CR5","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1128\/JVI.03656-14","volume":"89","author":"Y Huang","year":"2015","unstructured":"Huang, Y., Chen, Z., Huang, J., Fu, Z. & He, B. Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection. J. Virol. 89, 3427\u20133429 (2015).","journal-title":"J. Virol."},{"key":"851_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2217\/fvl.10.88","volume":"6","author":"DC Hooper","year":"2011","unstructured":"Hooper, D. C., Roy, A., Kean, R. B., Phares, T. W. & Barkhouse, D. A. Therapeutic immune clearance of rabies virus from the CNS. Future Virol. 6, 387\u2013397 (2011).","journal-title":"Future Virol."},{"key":"851_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","volume":"489","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology 489, 165\u2013172 (2016).","journal-title":"Virology"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"e0004746","DOI":"10.1371\/journal.pntd.0004746","volume":"10","author":"M Schnee","year":"2016","unstructured":"Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"851_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0032-6","volume":"2","author":"J Lutz","year":"2017","unstructured":"Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).","journal-title":"NPJ Vaccines"},{"key":"851_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12985-022-01919-7","volume":"19","author":"J Li","year":"2022","unstructured":"Li, J. et al. An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs. Virol. J. 19, 184 (2022).","journal-title":"Virol. J."},{"key":"851_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.7774\/cevr.2015.4.1.68","volume":"4","author":"MM Venkataswamy","year":"2015","unstructured":"Venkataswamy, M. M. et al. Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes. Clin. Exp. Vaccin. Res. 4, 68\u201374 (2015).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"851_CR12","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.vaccine.2016.12.031","volume":"35","author":"L Wijaya","year":"2017","unstructured":"Wijaya, L. et al. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus-specific antibody and T cell response in healthy adult volunteers. Vaccine 35, 1175\u20131183 (2017).","journal-title":"Vaccine"},{"key":"851_CR13","doi-asserted-by":"publisher","unstructured":"Overduin, L. A., van Dongen, J. J. M. & Visser, L. G. The cellular immune response to rabies vaccination: a systematic review. Vaccines 7, https:\/\/doi.org\/10.3390\/vaccines7030110 (2019).","DOI":"10.3390\/vaccines7030110"},{"key":"851_CR14","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1128\/JVI.01298-15","volume":"89","author":"A Bauer","year":"2015","unstructured":"Bauer, A., Nolden, T., Nemitz, S., Perlson, E. & Finke, S. A dynein light chain 1 binding motif in rabies virus polymerase L protein plays a role in microtubule reorganization and viral primary transcription. J. Virol. 89, 9591\u20139600 (2015).","journal-title":"J. Virol."},{"key":"851_CR15","doi-asserted-by":"publisher","unstructured":"Ogino, T. & Green, T. J. Transcriptional control and mRNA capping by the GDP polyribonucleotidyltransferase domain of the rabies virus large protein. Viruses 11, https:\/\/doi.org\/10.3390\/v11060504 (2019).","DOI":"10.3390\/v11060504"},{"key":"851_CR16","doi-asserted-by":"publisher","unstructured":"Ogino, M., Ito, N., Sugiyama, M. & Ogino, T. The rabies virus L protein catalyzes mRNA capping with GDP polyribonucleotidyltransferase activity. Viruses 8, https:\/\/doi.org\/10.3390\/v8050144 (2016).","DOI":"10.3390\/v8050144"},{"key":"851_CR17","doi-asserted-by":"publisher","first-page":"e00826","DOI":"10.1128\/JVI.00826-17","volume":"91","author":"K Nakagawa","year":"2017","unstructured":"Nakagawa, K. et al. Molecular function analysis of rabies virus RNA polymerase L protein by using an L gene-deficient virus. J. Virol. 91, e00826\u201300817 (2017).","journal-title":"J. Virol."},{"key":"851_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/JVI.02050-15","volume":"90","author":"D Tian","year":"2016","unstructured":"Tian, D. et al. Critical role of K1685 and K1829 in the large protein of rabies virus in viral pathogenicity and immune evasion. J. Virol. 90, 232\u2013244 (2016).","journal-title":"J. Virol."},{"key":"851_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4149\/av_2017_306","volume":"61","author":"IS Santos Katz","year":"2017","unstructured":"Santos Katz, I. S. et al. Large protein as a potential target for use in rabies diagnostics. Acta Virol. 61, 280\u2013288 (2017).","journal-title":"Acta Virol."},{"key":"851_CR20","doi-asserted-by":"publisher","first-page":"e2057","DOI":"10.1371\/journal.pone.0002057","volume":"3","author":"O Delmas","year":"2008","unstructured":"Delmas, O. et al. Genomic diversity and evolution of the lyssaviruses. PLoS ONE 3, e2057 (2008).","journal-title":"PLoS ONE"},{"key":"851_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1099991","volume":"13","author":"S Bai","year":"2022","unstructured":"Bai, S. et al. A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. Front. Immunol. 13, 1099991 (2022).","journal-title":"Front. Immunol."},{"key":"851_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-4939-1115-8_17","volume":"1184","author":"M Wang","year":"2014","unstructured":"Wang, M. & Claesson, M. H. Classification of human leukocyte antigen (HLA) supertypes. Methods Mol. Biol. 1184, 309\u2013317 (2014).","journal-title":"Methods Mol. Biol."},{"key":"851_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2172-9-1","volume":"9","author":"J Sidney","year":"2008","unstructured":"Sidney, J., Peters, B., Frahm, N., Brander, C. & Sette, A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 9, 1 (2008).","journal-title":"BMC Immunol."},{"key":"851_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00251-011-0513-0","volume":"63","author":"J Greenbaum","year":"2011","unstructured":"Greenbaum, J. et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63, 325\u2013335 (2011).","journal-title":"Immunogenetics"},{"key":"851_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/msb.2011.75","volume":"7","author":"F Sievers","year":"2011","unstructured":"Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"851_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","volume":"11","author":"TJ O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell, T. J., Rubinsteyn, A. & Laserson, U. MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing. Cell Syst. 11, 42\u201348.e47 (2020).","journal-title":"Cell Syst."},{"key":"851_CR27","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1007\/s00894-014-2278-5","volume":"20","author":"I Dimitrov","year":"2014","unstructured":"Dimitrov, I., Bangov, I., Flower, D. R. & Doytchinova, I. AllerTOP v.2\u2013a server for in silico prediction of allergens. J. Mol. Model 20, 2278 (2014).","journal-title":"J. Mol. Model"},{"key":"851_CR28","doi-asserted-by":"publisher","unstructured":"Sharma, N. et al. AlgPred 2.0: an improved method for predicting allergenic proteins and mapping of IgE epitopes. Brief Bioinform. 22, https:\/\/doi.org\/10.1093\/bib\/bbaa294 (2021).","DOI":"10.1093\/bib\/bbaa294"},{"key":"851_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/bioinformatics\/btt619","volume":"30","author":"I Dimitrov","year":"2014","unstructured":"Dimitrov, I., Naneva, L., Doytchinova, I. & Bangov, I. AllergenFP: allergenicity prediction by descriptor fingerprints. Bioinformatics 30, 846\u2013851 (2014).","journal-title":"Bioinformatics"},{"key":"851_CR30","doi-asserted-by":"publisher","first-page":"W36","DOI":"10.1093\/nar\/gkac446","volume":"50","author":"MN Nguyen","year":"2022","unstructured":"Nguyen, M. N. et al. AllerCatPro 2.0: a web server for predicting protein allergenicity potential. Nucleic Acids Res. 50, W36\u2013W43 (2022).","journal-title":"Nucleic Acids Res."},{"key":"851_CR31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against zika virus infection. Cell 168, 1114\u20131125.e1110 (2017).","journal-title":"Cell"},{"key":"851_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","volume":"212","author":"F Cliquet","year":"1998","unstructured":"Cliquet, F., Aubert, M. & Sagn\u00e9, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212, 79\u201387 (1998).","journal-title":"J. Immunol. Methods"},{"key":"851_CR33","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1093\/bioinformatics\/btac287","volume":"38","author":"S Samson","year":"2022","unstructured":"Samson, S., Lord, E. & Makarenkov, V. SimPlot++: a Python application for representing sequence similarity and detecting recombination. Bioinformatics 38, 3118\u20133120 (2022).","journal-title":"Bioinformatics"},{"key":"851_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00925-w","volume":"9","author":"J Li","year":"2024","unstructured":"Li, J. et al. Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques. NPJ Vaccines 9, 130 (2024).","journal-title":"NPJ Vaccines"},{"key":"851_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1288879","volume":"14","author":"M Li","year":"2023","unstructured":"Li, M. et al. An mRNA vaccine against rabies provides strong and durable protection in mice. Front. Immunol. 14, 1288879 (2023).","journal-title":"Front. Immunol."},{"key":"851_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2389115","volume":"13","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice. Emerg. Microbes Infect. 13, 2389115 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"851_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106425","volume":"185","author":"PC Yu","year":"2023","unstructured":"Yu, P. C. et al. A novel mRNA rabies vaccine as a promising candidate for rabies post-exposure prophylaxis protects animals from different rabies viruses. Micro. Pathog. 185, 106425 (2023).","journal-title":"Micro. Pathog."},{"key":"851_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-387040-7.00001-9","volume":"79","author":"AA Albertini","year":"2011","unstructured":"Albertini, A. A., Ruigrok, R. W. & Blondel, D. Rabies virus transcription and replication. Adv. Virus Res. 79, 1\u201322 (2011).","journal-title":"Adv. Virus Res."},{"key":"851_CR39","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1371\/journal.pntd.0000515","volume":"3","author":"HC Ertl","year":"2009","unstructured":"Ertl, H. C. Novel vaccines to human rabies. PLoS Negl. Trop. Dis. 3, e515 (2009).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"851_CR40","first-page":"360","volume":"83","author":"DL Knobel","year":"2005","unstructured":"Knobel, D. L. et al. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organ 83, 360\u2013368 (2005).","journal-title":"Bull. World Health Organ"},{"key":"851_CR41","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3389\/fmicb.2019.01630","volume":"10","author":"X Xie","year":"2019","unstructured":"Xie, X. et al. Influenza vaccine with consensus internal antigens as immunogens provides cross-group protection against influenza A viruses. Front. Microbiol 10, 1630 (2019).","journal-title":"Front. Microbiol"},{"key":"851_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38751-8","volume":"14","author":"W Tai","year":"2023","unstructured":"Tai, W. et al. An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants. Nat. Commun. 14, 2962 (2023).","journal-title":"Nat. Commun."},{"key":"851_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41586-021-04186-8","volume":"601","author":"L Swadling","year":"2022","unstructured":"Swadling, L. et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 601, 110\u2013117 (2022).","journal-title":"Nature"},{"key":"851_CR44","doi-asserted-by":"publisher","first-page":"8497","DOI":"10.1128\/jvi.71.11.8497-8503.1997","volume":"71","author":"F Rodriguez","year":"1997","unstructured":"Rodriguez, F., Zhang, J. & Whitton, J. L. DNA immunization- ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71, 8497\u20138503 (1997).","journal-title":"J. Virol."},{"key":"851_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109107","volume":"35","author":"F Gambino Jr","year":"2021","unstructured":"Gambino, F. Jr. et al. A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage. Cell Rep. 35, 109107 (2021).","journal-title":"Cell Rep."},{"key":"851_CR46","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","volume":"6","author":"DW Hawman","year":"2021","unstructured":"Hawman, D. W. et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a Cynomolgus macaque model. Nat. Microbiol 6, 187\u2013195 (2021).","journal-title":"Nat. Microbiol"},{"key":"851_CR47","doi-asserted-by":"publisher","first-page":"e01414","DOI":"10.1128\/JVI.01414-21","volume":"95","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Colloidal manganese salt improves the efficacy of rabies vaccines in mice, cats, and dogs. J. Virol. 95, e01414\u2013e01421 (2021).","journal-title":"J. Virol."},{"key":"851_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39421-5","volume":"14","author":"F Hellgren","year":"2023","unstructured":"Hellgren, F. et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat. Commun. 14, 3713 (2023).","journal-title":"Nat. Commun."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00851-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T12:02:28Z","timestamp":1744977748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00851-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00851-5","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors declare no competing interests. Dr. Jianqing Xu, Dr. Xiaoyan Zhang, and Ms. Shimeng Bai are applying for a patent from the Chinese Patent Office, which is relevant to this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}